Reading Hospital, McGlinn Cancer Institute — West Reading, Pennsylvania

Reading Hospital, McGlinn Cancer Institute is a clinical research site located in West Reading, Pennsylvania, United States 19611.

Crixeo Health Trust Score: 54/100 (POOR). This profile has not yet been claimed by the site owner.

Reading Hospital, McGlinn Cancer Institute has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer.

Sponsors: Daiichi Sankyo.

Sponsor Feasibility Report

Trust Score: 54/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Reading Hospital, McGlinn Cancer Institute?

Reading Hospital, McGlinn Cancer Institute has a Crixeo Trust Score of 54/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Reading Hospital, McGlinn Cancer Institute conducted?

Reading Hospital, McGlinn Cancer Institute has 1 clinical trials on record, with 1 currently active. Their work covers HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer.

Is Reading Hospital, McGlinn Cancer Institute accredited by Crixeo Health?

Reading Hospital, McGlinn Cancer Institute has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Reading Hospital, McGlinn Cancer Institute?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.